GIULIANI, Nicola
 Distribuzione geografica
Continente #
NA - Nord America 9.031
EU - Europa 6.978
AS - Asia 4.806
SA - Sud America 208
AF - Africa 106
Continente sconosciuto - Info sul continente non disponibili 19
OC - Oceania 4
Totale 21.152
Nazione #
US - Stati Uniti d'America 8.853
CN - Cina 2.756
IE - Irlanda 1.613
SE - Svezia 1.483
SG - Singapore 1.393
FI - Finlandia 1.047
IT - Italia 773
DE - Germania 726
UA - Ucraina 624
TR - Turchia 463
BR - Brasile 179
FR - Francia 173
CA - Canada 168
GB - Regno Unito 144
AT - Austria 96
CI - Costa d'Avorio 82
IN - India 79
RO - Romania 65
BE - Belgio 61
CZ - Repubblica Ceca 46
NL - Olanda 31
RU - Federazione Russa 22
EU - Europa 18
BD - Bangladesh 17
IR - Iran 17
LT - Lituania 13
BG - Bulgaria 9
HK - Hong Kong 9
ID - Indonesia 9
ES - Italia 8
IL - Israele 8
PK - Pakistan 8
AE - Emirati Arabi Uniti 6
CO - Colombia 6
EC - Ecuador 5
LV - Lettonia 5
MA - Marocco 5
NG - Nigeria 5
PL - Polonia 5
AR - Argentina 4
CH - Svizzera 4
JP - Giappone 4
LU - Lussemburgo 4
PY - Paraguay 4
SC - Seychelles 4
TW - Taiwan 4
UZ - Uzbekistan 4
VE - Venezuela 4
AU - Australia 3
BO - Bolivia 3
CM - Camerun 3
CR - Costa Rica 3
DK - Danimarca 3
KG - Kirghizistan 3
KH - Cambogia 3
KZ - Kazakistan 3
MD - Moldavia 3
MX - Messico 3
PH - Filippine 3
QA - Qatar 3
RS - Serbia 3
SK - Slovacchia (Repubblica Slovacca) 3
AM - Armenia 2
CL - Cile 2
EE - Estonia 2
HR - Croazia 2
JO - Giordania 2
KE - Kenya 2
NO - Norvegia 2
OM - Oman 2
PS - Palestinian Territory 2
PT - Portogallo 2
SM - San Marino 2
AL - Albania 1
AO - Angola 1
BN - Brunei Darussalam 1
BY - Bielorussia 1
BZ - Belize 1
CY - Cipro 1
DZ - Algeria 1
EG - Egitto 1
GA - Gabon 1
GH - Ghana 1
GR - Grecia 1
GT - Guatemala 1
HU - Ungheria 1
IQ - Iraq 1
JM - Giamaica 1
NP - Nepal 1
NZ - Nuova Zelanda 1
PE - Perù 1
PR - Porto Rico 1
TH - Thailandia 1
VN - Vietnam 1
XK - ???statistics.table.value.countryCode.XK??? 1
Totale 21.152
Città #
Chandler 1.645
Dublin 1.607
Singapore 1.057
Santa Clara 822
Jacksonville 758
Beijing 628
Ashburn 608
Boardman 435
Nanjing 406
Izmir 404
Dearborn 382
Parma 355
Ann Arbor 346
Princeton 323
Shanghai 305
San Mateo 233
Wilmington 186
Shenyang 158
New York 156
Kunming 145
Toronto 138
Marseille 137
Nanchang 135
Helsinki 126
Düsseldorf 114
Hebei 105
Jinan 102
Des Moines 87
Hefei 87
Vienna 83
Abidjan 82
Jiaxing 78
Bremen 74
Tianjin 73
Los Angeles 72
Munich 64
Seattle 63
Brussels 61
Changsha 57
Woodbridge 54
Kocaeli 52
Council Bluffs 47
Hangzhou 43
Focsani 39
Pune 39
Brno 37
Norwalk 37
Milan 34
Dallas 33
Guangzhou 30
Grafing 29
Zhengzhou 28
Houston 26
Fremont 21
London 21
Mestre 21
Nuremberg 21
Ningbo 20
Augusta 18
Taizhou 18
Chengdu 17
Borås 16
Fairfield 16
Haikou 16
Amsterdam 15
Lanzhou 15
Leawood 15
Rockville 15
Washington 15
Bologna 14
Fuzhou 14
Ottawa 14
Phoenix 14
Redmond 14
Wuhan 14
Rome 13
São Paulo 13
Cambridge 12
Chongqing 12
Frankfurt am Main 12
Timisoara 12
Modena 11
Monmouth Junction 11
Taiyuan 11
Edinburgh 10
Palermo 10
Trezzano Sul Naviglio 10
Jakarta 9
Jesi 9
Rho 9
Moscow 8
Sofia 8
Torino 8
Xian 8
Ahmedabad 7
Auburn Hills 7
Central 6
Chicago 6
Madrid 6
Nerviano 6
Totale 13.823
Nome #
Angiopoietin-1 and Osteopontin Expression by CD138+ Myeloma Cells Rather Than VEGF and CD45 Correlates with Bone Marrow Angiogenesis in Multiple Myeloma Patients at the Diagnosis 124
The Proteasome and Myeloma-Associated Bone Disease 119
Dependence on glutamine uptake and glutamine addiction characterize myeloma cells: a new attractive target 116
Are the Myeloma bone microevironment cells tumoral or not? 115
Hypoxia and Hypoxia Inducible Factor (HIF)-1{alpha} in Multiple Myeloma: Effect on the Pro-Angiogenic Signature of Myeloma Cells and the Bone Marrow Microenvironment 114
Neurofibromatosis type I and multiple myeloma coexistence: A possible link? 113
Co-existence of Philadelphia chromosome positive acute megakaryoblastic and B-lymphoblastic mixed blast crisis of chronic myeloid leukemia with chronic lymphocytic leukemia 112
Bone marrow CX3CL1/Fractalkine is a new player of the pro-angiogenic microenvironment in multiple myeloma patients 111
Osteolytic lesions, cytogenetic features and bone marrow levels of cytokines and chemokines in multiple myeloma patients: Role of chemokine (C-C motif) ligand 20 110
Ammonium Production and Glutamine-Addiction of Myeloma Cells: New Attractive Targets in Multiple Myeloma 108
HOXB7 expression by myeloma cells regulates their pro-angiogenic properties in multiple myeloma patients 106
CC-4047 (Pomalidomide) inhibits multiple myeloma-induced osteoclast formation targeting RANKL in the bone marrow microenvironment 103
HOXB7 is a key gene involved in Myeloma cell growth and Myeloma-induced angiogenesis in Multiple Myeloma patients 103
Myeloma cells inhibit non-canonical wnt co-receptor ror2 expression in human bone marrow osteoprogenitor cells: effect of wnt5a/ror2 pathway activation on the osteogenic differentiation impairment induced by myeloma cells 102
Human myeloma cells produce angiopoietin-1 but not angiopoietin-2: potential relationship with myeloma-induced angiogenesis 101
Bisphosphonates stimulate formation of osteoblast precursors and mineralized nodules in murine and human bone marrow cultures in vitro and promote early osteoblastogenesis in young and aged mice in vivo 101
Hypoxia and hypoxia inducible factor (HIF)-1α in Multiple Myeloma patients: role in the angiogenic switch 101
Activation of non-canonical wnt pathway in human mesenchymal cells affects osteogenic differentiation: a potential target in Multiple Myeloma microenvironment 99
Bone marrow Dikkopf-1 levels are a new independent risk factor for progression in patients with smouldering myeloma 99
The homeobox gene HOXB7 regulates the production of pro-angiogenic molecole by myeloma cells and it is a target in myeloma-induced angiogenesis 98
Expression of CD38 in myeloma bone niche: A rational basis for the use of anti-CD38 immunotherapy to inhibit osteoclast formation 98
Novel targets for the treatment of relapsing multiple myeloma 98
CD14+CD16+ monocytes are involved in daratumumab-mediated myeloma cells killing and in anti-CD47 therapeutic strategy 98
The osteoblastic niche in the context of multiple myeloma 97
Chemokine receptors CXCR3 and CXCR4 expression in B cell and plasma cell malignancy 96
Application of next-generation sequencing for the genomic characterization of patients with smoldering myeloma 96
The Immunomodulatory drugs Lenalidomide and Pomalidomide inhibit multiple myeloma-induced osteoclast formation and RANKL/OPG ratio in myeloma microenvironment targeting the expression of adhesion molecules 95
Bone marrow endothelial cells carry bcr/abl fusion gene from chronic myeloid leukemia patients 95
Glutamine dependence and PIK3CA mutations in colon-rectal cancer cells: ATF4 enters the stage 94
The IMID CC-4047 (Pomalidomide) inhibits myeloma-induced osteoclast formation 94
Angiopoietins expression by human myeloma cells 93
BCR/ABL fusion gene is detected in chronic myeloid leukemia endothelial cells 93
(2S,4R)-4-fluoroglutamine is converted into (2S,4R)-4-fluoroglutamate by glutaminase activity and may be exploited as a PET tracer in glutamine-addicted cancers 92
Bovine pestivirus is a new alternative virus for multiple myeloma oncolytic virotherapy 91
Oncolytic virotherapy and microenvironment in multiple myeloma 91
Serum concentrations of proinflammatory cytokines in Graves' disease: effect of treatment, thyroid function, ophthalmopathy and cigarette smoking 90
IL-7 is induced by IL-6 in human myeloma cells: role in multiple myeloma 90
Possible targets to treat myeloma-related osteoclastogenesis 90
LENALIDOMIDE INCREASES HUMAN DENDRITIC CELL MATURATION MODULATING BOTH MONOCYTE DIFFERENTIATION AND MESENCHYMAL STROMAL CELL INHIBITORY PROPERTIES 90
Bone Marrow Remodelling and Topographic Redistribution of CD34 Positive Progenitors Characterize the Progression of Myelodysplastic Syndromes and Their Evolution to AML 90
A Rare Case of Systemic AL Amyloidosis with Muscle Involvement: A Misleading Diagnosis 89
A simplified sars-cov-2 pseudovirus neutralization assay 89
Stem cell architecture drives myelodysplastic syndrome progression and predicts response to venetoclax-based therapy 88
Modulation of non canonical wnt5a/ror2 signaling pathway in human mesenchymal cells increases osteogenic differentiation counterbalancing the effect of myeloma cells 87
Hypoxia-Inducible Factor (HIF)-1 alpha Inhibitionin Myeloma Cells Significantly Increases the Anti-Myeloma Effect of Lenalidomide in Vivo 87
5-HT3 serotonergic receptor mediation of hypoglycemia-induced arginine-vasopressin but not oxytocin secretion in normal men. 87
[18F](2S,4R)-4-Fluoroglutamine as a New Positron Emission Tomography Tracer in Myeloma 87
Analysis of lineage involvment in Philadelphia chromosome positive acute lymphoblastic leukaemia 86
Hematologic malignancies with extramedullary spread of disease. Case 1. Multiple myeloma with extramedullary involvement of the pleura and testes 86
Increased osteocyte death in multiple myeloma patients: role in myeloma-induced osteoclast formation 86
Oxygen tension in the bone marrow (BM) of patients with malignant and indolent monoclonal gammopathy: role of hypoxia and hypoxia-inducible factor (HIF)-1{alpha} in the regulation of gene expression and pro-angiogenic profiles of CD138+ cells 86
Angiopoietin-1 and osteopontin expression by CD138+myeloma cells rather than VEGF and CD45 correlates with bone marrow angiogenesis in Multiple Myeloma patients at the diagnosis. 86
Bisphosphonates inhibit IL-6 production by human osteoblast-like cells 85
HOXB7 is critically involved in Multiple Myeloma-induced angiogenic switch 85
Phase II Study of the Combination of Interleukin-2 with Zoledronic Acid As Maintenance Therapy Following Autologous Stem Cell Transplant in Patients with Multiple Myeloma 85
Interleukin-27 acts as multifunctional antitumor agent in multiple myeloma 85
Myeloma Cells Deplete Bone Marrow Glutamine and Inhibit Osteoblast Differentiation Limiting Asparagine Availability 85
Myeloma cells block RUNX2/CBFA1 activity in human bone marrow osteoblast progenitors and inhibit osteoblast formation and differentiation 84
Angiogenic switch in multiple myeloma patients 84
Angiogenic properties of human myeloma cells: role of angiopoietin system 84
Bone Marrow DKK-1 Levels in Smoldering Multiple Myeloma Patients: A New Independent Risk Factor for Progression 84
Functional consequences of low activity of transport system a for neutral amino acids in human bone marrow mesenchymal stem cells 84
PD-L1/PD-1 Pattern of Expression Within the Bone Marrow Immune Microenvironment in Smoldering Myeloma and Active Multiple Myeloma Patients 84
Pro-angiogenetic properties of human myeloma cells: production of angiopoietin-1 and its potential relationship with myeloma-induced angiogenesis 83
Addition of Bortezomib to High Dose Melphalan As Conditioning Regimen for Autologous Stem Cell Transplantation Improves the Response Rate in Newly Diagnosed Multiple Myeloma Patients 83
Bone marrow stromal cell-fueled multiple myeloma growth and osteoclastogenesis are sustained by protein kinase CK2 83
DEPENDENCE ON GLUTAMINE UPTAKE OF MYELOMA CELLS DELINEATES A NEW ATTRACTIVE THERAPEUTIC STRATEGY 83
The anti-tumoral effect of lenalidomide is increased in vivo by hypoxia-inducible factor (HIF)-1α inhibition in myeloma cells 83
Non canonical wnt signal pathway (Wnt5a/ror2) activation stimulates the osteogenic differentiation process of bone mesenchymal cells being a potential target in multiple myeloma bone disease 82
GPNA inhibits the sodium-independent transport system l for neutral amino acids 81
ILF2-YB1 Protein Interaction Modulates RNA Splicing to Induce Resistance to Chemotherapy in High Risk Multiple Myeloma 81
Do human myeloma cells directly produce basic FGF? 81
EXPRESSION OF CD38 AND ECTOENZYMES OF THE ADENOSINERGIC PATHWAYS IN MYELOMA BONE NICHE: A RATIONAL BASIS FOR THE USE OF DARATUMUMAB TO TARGET OSTEOCLAST FORMATION IN MULTIPLE MYELOMA 81
Bone microenvironment cells show a different pattern of gene expression profiling in relationship with the presence of osteolytic bone lesions in Multiple Myeloma patients 80
Galectin-1 Is Highly Expressed By Myeloma Cells and the Bone Marrow Microenvironment and Its Suppression Delineates a New Therapeutic in Vitro and in Vivo Strategy in Multiple Myeloma 80
Immune tolerance induction by nonmyeloablative haploidentical HSCT combining T-cell depletion and posttransplant cyclophosphamide 80
VASCULAR ENDOTHELIAL GROWTH FACTOR SECRETION BY MYELOMA CELLS IS INHIBITED BY DOWN-MODULATING ERK PROTEIN KINASE ACTIVITY 79
Angiopoietin-1 and myeloma-induced angiogenesis 79
CC-Chemokine Ligand 20/Macrophage Inflammatory Protein-3A and CC-Chemokine Receptor 6 Are Overexpressed in Myeloma Microenvironment Related to Osteolytic Bone Lesions 79
CXCR3 and its binding chemokines in myeloma cells: expression of isoforms and potential relationships with myeloma cell proliferation and survival. 79
Expression and role of chemokine receptor CXCR3 in multiple myeloma 79
The activation of wnt5a-mediated non canonical wnt signaling in human bone marrow osteoprogenitor cells increases osteoblastogenesis and counterbalances the inhibitory effect of myeloma cells on ror2/fzd5 expression 79
Macrophage inflammatory protein (MIP)-3 alpha/CCL20 and its receptor CCR6 are overexpressed in the bone microenvironment and involved in osteoclast formation in multiple myeloma patients. 79
Amlexanox inhibition of TBK1/IKK epsilon Signaling Is a Novel Therapeutic Approach for Multiple Myeloma-Induced Bone Disease. 79
Elotuzumab, lenalidomide, and dexamethasone as salvage therapy for patients with multiple myeloma: Italian, multicenter, retrospective clinical experience with 300 cases outside of controlled clinical trials 79
Ectopic production of osteopontin by human myeloma cells and its involvement in myeloma induced angiogenesis 79
Generation and Characterization of Microvesicles after Daratumumab Interaction with Myeloma Cells 79
Osteopontin is produced by human multiple myeloma cells 78
Myeloma cells inhibit the non-canonical wnt co-receptor ror2 in human mesenchymal/osteoprogenitor cells: effect of wnt5a/ror2 pathway activation on mm-induced impairment of the osteogenic differentiation process 78
A Mouse Model of Telomere Dysfunction Recapitulates Hallmark Features of Human Myelodysplastic Syndrome 78
ADENOSINE IN THE MYELOMA BONE MARROW NICHE: IMMUNE CHECKPOINT AND KEY PLAYER IN DISEASE PROGRESSION 78
Effects of hematin and Mössbauer gamma-radiation on human osteosarcoma cell lines 78
Galectin-1 suppression delineates a new strategy to inhibit myeloma-induced angiogenesis and tumoral growth in vivo 78
Serum interleukin-6, soluble interleukin-6 receptor and soluble gp130 exhibit different patterns of age- and menopause-related changes 77
Pan-aurora kinase inhibitor MK-0457 synergistically potentiates Apo2l/TRAIL cytotoxicity in Multiple Mieloma cells sensitive and resistant to bortezomib 77
CK2 Kinase Inhibitors Display Anti-Myeloma Effects and Antagonize Osteoclast Activity in Models of Multiple Myeloma Bone Marrow Microenvironment 77
Bortezomib improves bone integrity in multiple myeloma patients by blocking osteocyte death and autophagy 77
The anti-myeloma effect of Lenalidomide is increased by hypoxia-inducible factor (HIF)-1a inhibition in multiple myeloma cells both in vitro and in vivo 77
Bone marrow monocyte / macrophage derived activin a mediates the osteoclastogenic effects of IL-3 in myeloma 77
Autologous bone marrow transplantation in acute myeloid leukemia: a single center experience 77
Totale 8.936
Categoria #
all - tutte 88.301
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 88.301


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020992 0 0 0 0 0 0 0 70 255 373 102 192
2020/20211.687 77 171 139 18 244 24 144 47 377 87 292 67
2021/20221.590 31 23 26 110 37 57 199 202 77 145 128 555
2022/20236.260 724 647 387 452 535 671 158 400 1.960 74 187 65
2023/20242.283 110 237 55 58 191 623 195 163 54 126 152 319
2024/20253.514 118 403 435 583 801 690 288 196 0 0 0 0
Totale 21.590